On September 24, CANSINOBIO fell 5.22% in regular trading, trading at HK$30.16/share, with turnover of HK$104 million. The decline came after the stock had surged over 25% across five consecutive trading sessions, triggering profit-taking pressure.

The prior rally was driven by multiple catalysts, including a strategic cooperation framework agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines, as well as broader enthusiasm around the mRNA oncology vaccine theme following Moderna's Phase III clinical success with its personalized mRNA cancer vaccine. A research note from CLSA had characterized the Moderna breakthrough as a platform-level valuation re-rating event and noted that CANSINOBIO's development approach and antigen design closely mirror Moderna's.

The broader biotechnology sector weighed heavily on the stock on the same day. INNOCARE fell 11.11%, REMEGEN dropped 7.99%, INNOVENT BIO declined 3.38%, AKESO slipped 2.92%, and BEONE MEDICINES lost 1.47%, reflecting widespread sector pressure that amplified the pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)